TickerFacts.

Company research / LLY

Eli Lilly & Co (LLY)

Build a valuation ↗↓ Download CSV

SEC name ELI LILLY & Co · CIK 0000059478 · NYSE · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated IN
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Eli Lilly & Co reported revenue of $65.18B. Revenue grew 44.7% from the prior annual period.

Key ratios (year ended 2025-12-31)

83.0%
Gross margin (computed)
31.7%
Net margin
77.8%
Return on year-end equity
44.7%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-09-22

Headquarters locality: Indianapolis · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

Period ended2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$65.18B$45.04B$34.12B$28.54B$28.32B$24.54B$22.32B$21.49B$19.97B$21.22B
Cost of Revenue$11.05B$8.42B$7.08B$6.63B$7.31B$5.48B$4.72B$4.68B$4.45B$5.71B
Gross Profit (computed)$54.13B$36.62B$27.04B$21.91B$21.01B$19.06B$17.60B$16.81B$15.53B$15.51B
R&D Expense$13.34B$10.99B$9.31B$7.19B$6.93B$5.98B$5.59B$5.05B$5.10B$5.31B
Depreciation & Amortization$2.00B$1.77B$1.53B$1.52B$1.55B$1.32B$1.23B$1.61B$1.57B$1.50B
Net Income$20.64B$10.59B$5.24B$6.24B$5.58B$6.19B$8.32B$3.23B-$204.10M$2.74B
EPS (Diluted)$22.95$11.71$5.80$6.90$6.12$6.79$8.89$3.13-$0.19$2.58
Total Assets$112.48B$78.72B$64.01B$49.49B$48.81B$46.63B$39.29B$43.91B$44.98B$38.81B
Long-Term Debtn/a$29.47B$19.10B$14.82B$16.74B$16.35B$13.64Bn/an/a$9.01B
Shareholders' Equity$26.54B$14.27B$10.77B$10.65B$8.98B$5.64B$2.61B$9.83B$11.59B$14.01B
Cash & Equivalents$7.27B$3.27B$2.82B$2.07B$3.82B$3.66B$2.34B$7.32B$6.54B$4.58B
Operating Cash Flow$16.81B$8.82B$4.24B$7.59B$7.37B$6.50B$4.84B$5.52B$5.62B$4.85B
Capital Expenditures$7.84B$5.06B$3.45B$1.85B$1.31B$1.39B$1.03B$1.21B$1.08B$1.04B
Free Cash Flow$8.97B$3.76B$792.00M$5.73B$6.06B$5.11B$3.80B$4.31B$4.54B$3.81B
Share Repurchases$4.11B$2.50B$750.00M$1.50B$1.25B$500.00M$4.40B$4.15B$299.80M$600.10M
Dividends Paid$5.38B$4.68B$4.07B$3.54B$3.09B$2.69B$2.41B$2.31B$2.19B$2.16B
Dividends Per Share$6.23$5.40$4.69$4.07$3.53$3.07$2.68$2.33$2.12$2.05
Weighted Average Diluted Shares899.30M904.10M903.30M904.62M911.68M912.50M935.68M1.03B1.05B1.06B
EPS (Basic)$23.00$11.76$5.82$6.93$6.15$6.82$8.93$3.14-$0.19$2.59

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView